US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Black Diamond Therapeutics, Inc. - Common Stock
(NQ:
BDTX
)
1.890
+0.010 (+0.53%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Black Diamond Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
September 02, 2026
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 05, 2026
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path
↗
June 06, 2026
Black Diamond Therapeutics (NASDAQ:BDTX) is positioning its lead oncology drug candidate, silevertinib, as a potential treatment for non-small cell lung cancer patients with non-classical EGFR...
Via
MarketBeat
What's Going On With Black Diamond Therapeutics Stock Tuesday?
↗
May 26, 2026
Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving averages, and price action.
Via
Benzinga
Which stocks are experiencing notable movement on Friday?
↗
May 22, 2026
Via
Chartmill
Keep an eye on the top gainers and losers in Friday's session.
↗
May 22, 2026
Via
Chartmill
Friday's session: gap up and gap down stocks
↗
May 22, 2026
Via
Chartmill
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
May 22, 2026
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
↗
May 21, 2026
Black Diamond Therapeutics (NASDAQ:BDTX) reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the...
Via
MarketBeat
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
May 21, 2026
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
May 19, 2026
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 07, 2026
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
April 21, 2026
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 16, 2026
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
March 02, 2026
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
December 03, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
December 02, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
November 06, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 06, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals
↗
October 10, 2025
4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.
Via
Benzinga
Black Diamond (BDTX) Q2 Loss Narrows 47%
↗
August 07, 2025
Via
The Motley Fool
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 07, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
May 29, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 12, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
March 31, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
These stocks have an unusual volume in today's session
↗
March 21, 2025
These stocks have an unusual volume in today's session
Via
Chartmill
Unusual volume stocks in Thursday's session
↗
March 20, 2025
Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session.
Via
Chartmill
These stocks are the most active in today's session
↗
March 19, 2025
These stocks are making the most noise in today's session. Stay tuned for the latest updates!
Via
Chartmill
What's going on in today's session
↗
March 19, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High
↗
March 19, 2025
As part of the deal, Servier will develop and commercialize the clinical-stage oncology company’s BDTX-4933, a molecule designed to address solid tumors, including non-small cell lung cancer.
Via
Stocktwits
< Previous
1
2
3
4
5
6
7
Next >
